Sign inSubscribe

modality directory

cell therapy clinical trial intelligence

Trials are included when the normalized modality field matches this therapeutic modality. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

12

Directory type

modality

Association rule

normalized field

NCT06128044
Source recordAI-normalized

A Phase 1, Multicenter, Open-Label Study of CB-012, a CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

CB-012, developed by Caribou Biosciences, Inc., is an allogeneic CAR-T cell therapy targeting CLL-1, specifically designed for patients with relapsed or refractory acute myeloid leukemia (AML). The therapy aims to address a significant unmet need in the AML market, particularly for patients who have limited treatment options after multiple lines of therapy. The competitive landscape includes other CAR-T therapies and emerging treatments targeting similar patient populations. However, the unique CRISPR-editing technology may provide a differentiation point in terms of efficacy and safety profile. The termination of this trial due to sponsor decision and pipeline reprioritization raises concerns regarding the asset's future and may indicate a strategic shift within Caribou's portfolio, necessitating further diligence on their remaining assets and overall pipeline strategy.

AI analysis

Indication: Acute Myeloid Leukemia, in Relapse

Modality: cell therapy

Target: C-type lectin-like molecule-1 (CLL-1)

Sponsor: Caribou Biosciences, Inc.

Source URL: ClinicalTrials.gov

Source updated: Jun 11, 2025

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Condition normalized: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: C-type lectin-like molecule-1 (CLL-1)

Target normalized: C-type lectin-like molecule-1 (CLL-1)

Open report
NCT04037566
Source recordAI-normalized

A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.

The XYF19 CAR-T cell therapy targets CD19, a well-established antigen in B cell malignancies, particularly in relapsed or refractory CD19+ leukemia and lymphoma. The innovative approach of utilizing CRISPR technology to edit endogenous HPK1 may enhance the efficacy and safety profile of CAR-T therapies. The market for CAR-T therapies is expanding, with significant demand for novel treatments in hematological cancers. Competitive analysis indicates that while several CAR-T products exist, the unique genetic modification may provide a differentiated therapeutic option. Diligence should focus on regulatory pathways, potential partnerships with biotech firms, and the evolving landscape of CAR-T therapies in China and globally.

AI analysis

Indication: Leukemia Lymphocytic Acute (ALL) in Relapse

Modality: cell therapy

Target: CD19-specific CAR-T cells engineered with CRISPR to eliminate endogenous HPK1.

Sponsor: Xijing Hospital

Source URL: ClinicalTrials.gov

Source updated: Jul 30, 2019

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive

Condition normalized: Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: CD19-specific CAR-T cells engineered with CRISPR to eliminate endogenous HPK1.

Target normalized: CD19-specific CAR-T cells engineered with CRISPR to eliminate endogenous HPK1.

Open report
NCT04665076
Source recordAI-normalized

Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

Hebei Senlang Biotechnology Inc., Ltd. is conducting a multicenter clinical trial to evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed/refractory plasma cell tumors. The trial targets a niche but critical segment of the oncology market, specifically addressing patients who have limited treatment options due to the refractory nature of their disease. The competitive landscape includes established CAR-T therapies, such as those targeting BCMA, which have shown promise in similar patient populations. Successful outcomes could position Hebei Senlang favorably within the CAR-T market, potentially leading to partnerships or acquisitions, especially given the increasing interest in innovative therapies for hematological malignancies. However, the trial's non-randomized, single-arm design may limit the robustness of comparative efficacy claims against existing therapies.

AI analysis

Indication: Plasma Cell Tumors

Modality: cell therapy

Target: BCMA (B-cell maturation antigen), CD19, CD22, CD79

Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

Source URL: ClinicalTrials.gov

Source updated: Dec 11, 2020

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Plasma Cell Tumors

Condition normalized: Plasma Cell Tumors

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: BCMA (B-cell maturation antigen), CD19, CD22, CD79

Target normalized: BCMA (B-cell maturation antigen), CD19, CD22, CD79

Open report
NCT05123209
Source recordAI-normalized

Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients Wirh Advanced Liver Tumors

The IM83 CAR-T cell therapy, targeting GPC3 antigen, is positioned to address a significant unmet need in advanced hepatocellular carcinoma (HCC), particularly in patients who have failed first-line treatments. The market for liver cancer therapies is growing, driven by increasing incidence rates and a lack of effective second-line options. Given the specificity of the GPC3 target, IM83 may offer a competitive edge over existing therapies, particularly in the CAR-T space. However, the asset's success will depend on the outcomes of the ongoing trial and the competitive landscape, which includes other CAR-T therapies and novel systemic treatments for liver cancer.

AI analysis

Indication: Liver Cancer

Modality: cell therapy

Target: GPC3 antigen

Sponsor: Beijing Immunochina Medical Science & Technology Co., Ltd.

Source URL: ClinicalTrials.gov

Source updated: Nov 17, 2021

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Liver Cancer

Condition normalized: Liver Cancer

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: GPC3 antigen

Target normalized: GPC3 antigen

Open report
NCT03608631
Source recordAI-normalized

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.

AI analysis

Indication: KRAS NP_004976.2:p.G12D

Modality: cell therapy

Target: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Sponsor: M.D. Anderson Cancer Center

Source URL: ClinicalTrials.gov

Source updated: May 20, 2026

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Condition normalized: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Target normalized: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA

Open report
NCT06687564
Source recordAI-normalized

Role of ACTG2 Variants in Smooth Muscle Determination and Function in Pediatric Intestinal Pseudo-obstruction.

The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control / WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.

AI analysis

Indication: PIPO

Modality: cell therapy

Target: Biopsy

Sponsor: University Hospital, Grenoble

Source URL: ClinicalTrials.gov

Source updated: May 27, 2026

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: PIPO

Condition normalized: PIPO

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: Biopsy

Target normalized: Biopsy

Open report
NCT01061099
Source recordAI-normalized

A Pilot Study to Assess the Safety and Feasibility of Repeated Infusions of Mesenchymal Stromal Cells (MSC) in Children With Osteogenesis Imperfecta

This is a study to evaluate the safety and effectiveness of repeated Mesenchymal Stromal Cells (MSC) infusions to patients with Type II or III osteogenesis imperfecta (OI). Participants will receive MSC infusions approximately every 4 months to complete a total of 6 infusions over 20 months. Participants will be followed for 4 months post their last MSC infusion.

AI analysis

Indication: Osteogenesis Imperfecta Type II

Modality: cell therapy

Target: Mesenchymal Stromal Cells

Sponsor: Nationwide Children's Hospital

Source URL: ClinicalTrials.gov

Source updated: Apr 24, 2015

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III

Condition normalized: Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: Mesenchymal Stromal Cells

Target normalized: Mesenchymal Stromal Cells

Open report
NCT02172885
Source recordAI-normalized

Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).

AI analysis

Indication: Osteogenesis Imperfecta

Modality: cell therapy

Target: Mesenchymal Stem Cells

Sponsor: Hospital de Cruces

Source URL: ClinicalTrials.gov

Source updated: Oct 03, 2023

Ingested: Jun 11, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Osteogenesis Imperfecta

Condition normalized: Osteogenesis Imperfecta

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: Mesenchymal Stem Cells

Target normalized: Mesenchymal Stem Cells

Open report
NCT00979342
Source recordAI-normalized

Interlace Medical Comparative Sedation Study

The purpose of this study is to develop a recommended local anesthetic protocol and post-treatment pain management regimen, in order to assure patient comfort during office-based treatment with the MyoSure Hysteroscopic Tissue Removal Device. Subject self-reported pain scores (as rated on an 11 point scale) will be compared at multiple time intervals between all treatment groups.

AI analysis

Indication: Uterine Fibroids

Modality: cell therapy

Target: Hysteroscopic Morcellator

Sponsor: Hologic, Inc.

Source URL: ClinicalTrials.gov

Source updated: Jul 23, 2010

Ingested: Jun 09, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Uterine Fibroids, Polyps

Condition normalized: Uterine Fibroids, Polyps

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: Hysteroscopic Morcellator

Target normalized: Hysteroscopic Morcellator

Open report
NCT04093336
Source recordAI-normalized

Effect of Human Umbilical Cord Mesenchymal Stem Cells(MSCs) Transplantation for on Prognosis of Acute Cerebral Infarction Patients

This is a placebo controlled, randomized, double blinded study including Phase 1 and Phase 2. Phase I study is a safety assessment and Phase 2 study is incline to assess effectiveness of MSCs. Potential subjects must be screened and consented before enrolled. The primary objective of this study is to determine the effects of early intravenous infusion of allogeneic human umbilical cord mesenchymal stem cells (HucMSCs or MSCs used in the following section) for patients with acute ischemic stroke. Eligible patients will receive a single dose of MSCs or placebo within 24 hours after stroke. Patients will be followed for 2 years post infusion for safety and efficacy (change in neurological symptoms and quality of life). Assessments will occur during transplantation and at 3,7, 14 days and1,3, 6, 12, 18 and 24 months after infusions of stem cells.

AI analysis

Indication: Infarction, Middle Cerebral Artery

Modality: cell therapy

Target: human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Sponsor: Shanghai East Hospital

Source URL: ClinicalTrials.gov

Source updated: Apr 18, 2023

Ingested: Jun 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Infarction, Middle Cerebral Artery, Infarction, Anterior Cerebral Artery, Cerebral Infarction, Stroke, Ischemic, Acute Stroke, Brain Infarction, Infarction, PCA, Infarction, Posterior Circulation, Brain

Condition normalized: Infarction, Middle Cerebral Artery, Infarction, Anterior Cerebral Artery, Cerebral Infarction, Stroke, Ischemic, Acute Stroke, Brain Infarction, Infarction, PCA, Infarction, Posterior Circulation, Brain

Modality raw: cell therapy

Modality normalized: cell therapy

Target raw: human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Target normalized: human umbilical cord mesenchymal stem cells, Placebo, standardized treatment

Open report
NCT04658914
Source recordAI-normalized

Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa

This clinical trial evaluates a novel trivalent VP8 subunit rotavirus vaccine in combination with the existing Rotarix vaccine to enhance immune response in infants in Zambia. The study aims to address the ongoing morbidity and mortality associated with rotavirus infections despite existing vaccination efforts.

AI analysis

Indication: Diarrhea

Modality: cell therapy

Target: Rotavirus

Sponsor: Centre for Infectious Disease Research in Zambia

Source URL: ClinicalTrials.gov

Source updated: May 15, 2025

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Diarrhea

Condition normalized: Diarrhea

Modality raw: Diarrhea

Modality normalized: cell therapy

Target raw: Rotavirus

Target normalized: Rotavirus

Open report
NCT02131766
Source recordAI-normalized

Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Overnight Control in Type 1 Diabetes

The USS Virginia Closed-Loop system aims to improve overnight blood glucose control in adults with Type 1 Diabetes (T1DM) compared to traditional sensor-augmented pump therapy. The study evaluates the feasibility and effectiveness of this system in an outpatient setting.

AI analysis

Indication: Diabetes Mellitus

Modality: cell therapy

Target: Type 1 Diabetes

Sponsor: University of Virginia

Source URL: ClinicalTrials.gov

Source updated: Apr 16, 2020

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by modality_normalized: cell therapy

View original source fields

Condition raw: Diabetes Mellitus

Condition normalized: Diabetes Mellitus

Modality raw: Diabetes Mellitus

Modality normalized: cell therapy

Target raw: Type 1 Diabetes

Target normalized: Type 1 Diabetes

Open report